Hans Biomed

Hans Biomed EBIT Margin

The EBIT Margin (Operating Margin) of Hans Biomed (042520.KQ) as of Nov 1, 2026 is 0.78 %. In the previous year, EBIT Margin (Operating Margin) was -5.79 % — a change of -113.40% (higher).

EBIT Margin

0.78 %

YoY

-113.40%

Last updated:

EBIT Margin (Operating Margin) of Hans Biomed is 2024 0.78 % . EBIT Margin (Operating Margin) of Hans Biomed was 2023 -5.79 % . It decreases by -113.40% higher compared to the previous year.

Hans Biomed's operating (EBIT) margin stands at 0.8%, up from -4.3% several years earlier.

The Hans Biomed EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2017
23.67 KRW
Jan 1, 2018
11.62 KRW
Jan 1, 2019
16.36 KRW
Jan 1, 2020
-4.25 KRW
Jan 1, 2021
-27.66 KRW
Jan 1, 2022
1.69 KRW
Jan 1, 2023
-5.79 KRW
Jan 1, 2024
0.78 KRW
The Hans Biomed EBIT Margin history
YEAREBIT MarginYoY
0.78 %-113.40%
-5.79 %-443.45%
1.69 %-106.10%
-27.66 %+550.18%
-4.25 %-126.00%
16.36 %+40.76%
11.62 %-50.91%
23.67 %+16.85%
20.26 %-6.16%
21.59 %+16.29%
18.57 %+9,466.09%
0.19 %+8.35%
0.18 %+389.68%
0.04 %-36.01%
0.06 %-61.08%
0.15 %-8.60%
0.16 %+12.55%
0.14 %-0.17%
0.14 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Hans Biomed Stock analysis

What does Hans Biomed do? Hans Biomed Corp manufactures and sells graft material and silicon products under brand names SureDerm, BellaGen, and GPS for skin-implant materials used in burn treatment and skin graft. The company offers bone-implant materials including allogeneic bones, xenogenous bones, and synthetic bones under SureFuse, ExFuse, and SureOss for dentistry and orthopedic applications. Silicone products such as BellaGel and Scar Clinic are utilized for scar treatment and breast implants. The firm also provides hair transplanters as part of its product portfolio. Skin-implant materials under SureDerm, BellaGen, and GPS are purchased by medical facilities for burn treatment and skin graft procedures. Bone-implant materials under SureFuse, ExFuse, and SureOss are bought by dental and orthopedic clinics for various surgical needs. Silicone products BellaGel and Scar Clinic are acquired by healthcare providers for scar management and breast implant surgeries. Hair transplanters are sold to medical institutions requiring such equipment. The company's primary revenue streams come from the sale of skin-implant materials, bone-implant materials, and silicone products across medical, dental, and orthopedic sectors. Medical facilities, dental clinics, and orthopedic practices represent key customer segments. Brand names SureDerm, BellaGen, GPS, SureFuse, ExFuse, SureOss, BellaGel, and Scar Clinic drive product differentiation and market positioning in the healthcare industry. Hans Biomed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Hans Biomed stock

EBIT Margin (Operating Margin) of Hans Biomed is 0.78 % in 2024.

EBIT Margin (Operating Margin) of Hans Biomed changed from -5.79 % to 0.78 %, representing a -113.40% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Hans Biomed since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Hans Biomed with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Hans Biomed

All Key Metrics — Hans Biomed